A Phase 1/2 clinical trial in patients with GATA2-related myelodysplastic syndromes (MDS)

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 14 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Sep 2021 New trial record
08 Sep 2021 According to a Jasper Therapeutics media release, it and the National Cancer Institute (NCI), part of the National Institutes of Health, have entered into a clinical trial agreement in which NCI will serve as the Investigational New Drug (IND) sponsor for this study
08 Sep 2021 According to a Jasper Therapeutics media release, it has initiated a Phase 1/2 clinical trial to evaluate JSP191, as a targeted, non toxic conditioning agent prior to allogeneic transplant in patients with GATA2-related myelodysplastic syndromes (MDS).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com